Secured Access to innovative medicines for CHildren, adolescents and young adults with cAncer

First published 01/02/2024

Last updated 17/10/2024

Data source

Human

Drug registry

Spontaneous reports of suspected adverse drug reactions

Download as PDF

Administrative details

PURI: https://redirect.ema.europa.eu/resource/1111161

Data source ID: 1111161

Name of data source: Secured Access to innovative medicines for CHildren, adolescents and young adults with cAncer

Data source acronym: SACHA France

Data holder: Gustave Roussy

Data source type: Drug registry
Spontaneous reports of suspected adverse drug reactions

Main financial support: Funds from patients organisations, charity and foundations
Other

Care setting: Hospital inpatient care
Hospital outpatient care
Secondary care – specialist level (ambulatory)

Data source qualification If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.: No

Data source website: https://www.gustaveroussy.fr/fr/sacha

Contact details

Pablo Berlanga

Main

pablo.berlanga@gustaveroussy.fr

Data source regions and languages

Data source countries: France

Data source languages: English

Data source establishment

Data source established: 01/01/2020

Data source time span: First collection: 01/01/2020
The date when data started to be collected or extracted.

Publications

Data source publications

Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE)